Creo Medical Group plc

("Creo" the "Company" or the "Group")

First Welsh adopter of Speedboat® technology for colon cancer

Aneurin Bevan University Health Board initiates Speedboat® pilot  

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the Aneurin Bevan University Health Board ("ABUHB") has initiated a six-month pilot of Creo's Speedboat® technology, becoming the first Health Board in Wales to implement the technology.

The news has been announced by ABUHB online and is available to view via the following link.

https://abuhb.nhs.wales/news/news/aneurin-bevan-university-health-board-leads-the-way-in-wales-with-innovative-speedboat-device-to-tackle-colon-cancer/

The full text is reproduced below:

Aneurin Bevan University Health Board Leads the Way in Wales

with Innovative Speedboat Device to Tackle Colon Cancer

Aneurin Bevan University Health Board (ABUHB) has become the first in Wales to pilot the groundbreaking Speedboat Submucosal Dissection (SSD) technology, transforming the treatment pathway for patients with complex colorectal polyps. Developed by Welsh med-tech company Creo Medical, this innovative device offers a minimally invasive alternative to traditional surgery, significantly improving patient outcomes and recovery times.

Currently, patients with complex polyps often face multiple procedures or major surgery, which can result in lengthy recovery times and higher risks. The Speedboat device allows clinicians to perform a single, minimally invasive procedure to remove polyps effectively, reducing the need for surgery and enabling faster patient recovery. Introducing this technology addresses a critical gap in treatment services in Wales.

Dr. Alka Joshi, Clinical Lead for the pilot, commented: "This pilot is a significant step forward for our patients. By utilising the Speedboat device, we can offer a more efficient, less invasive alternative to traditional surgical methods, improving outcomes and reducing waiting times."

Since the pilot's launch before Christmas, three patients have undergone the treatment successfully with no recorded complications. Each procedure was completed in a single session, and all patients were discharged the same day. One patient even resumed normal activities, including Christmas shopping, the very next day.

Backed by the Health Board's Clinical Safety and Effectiveness Group, the pilot is supported by Creo's on-site clinical education program, which reduces clinician training time from years to just months. This mentorship model enables ABUHB to embed the procedure at pace while ensuring safety and cost-effectiveness, creating a potential replicable blueprint for adoption across other health boards in Wales.

Rob Holcombe, Finance Director & Innovation Executive Lead at ABUHB, stated: "We are proud to champion this innovative Welsh technology in ABUHB. The early success of this pilot highlights the Board's commitment to delivering solutions that enhance patient care, reduce pressure on surgical services and demonstrate ABUHB's approach to adopting medical innovation through 'value- based health care' outcome evaluation."

The ABUHB video can be viewed here: https://vimeo.com/1053790954

Craig Gulliford, Chief Executive Officer of Creo, said: "As a Welsh company, it is exciting that the Aneurin Bevan team are the first in Wales to use our Speedboat for the benefit of its colon cancer patients; the SSD pilot in could enhance patient outcomes, reduce surgical waiting lists, and facilitate the wider adoption of this technique across other Health Boards in Wales."

For further information please contact: 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com